Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jan;8(1):53-6.
doi: 10.1111/j.1524-6175.2005.04140.x.

Pharmacotherapy review: calcium channel blockers

Domenic A Sica  1
Affiliations
Review

Pharmacotherapy review: calcium channel blockers

Domenic A Sica. J Clin Hypertens (Greenwich). 2006 Jan.

Abstract

As a drug class, calcium channel blockers encompass a heterogeneous group of compounds with distinctive structures and pharmacologic characteristics. These agents are widely used in the treatment of hypertension, chronic coronary ischemia, and/or supraventricular arrhythmias. Much of the early debate alluding to increased cardiovascular risk associated with calcium channel blocker use has been silenced by an array of outcomes trials that show these drugs to be both safe and effective in reducing hard cardiovascular end points. The most common side effects associated with calcium channel blockers are vasodilatory in nature and include a non-volume-dependent form of peripheral edema, flushing, and headache. Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control.

PubMed Disclaimer

References

    1. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206–1252. - PubMed
    1. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165: 1410–1419. - PubMed
    1. Frishman W, Sica DA. Calcium channel blockers. In: Frishman W, Sonnenblick S, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw‐Hill. 2003: 105–130.
    1. Staessen JA, Wang JG, Thijs L, et al. Cardiovascular protection and blood pressure reduction: A meta‐analysis. Lancet. 2001;358: 1305–1315. - PubMed
    1. Turnbull., For the Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood‐pressure lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet. 2003;362: 1527–1535. - PubMed

MeSH terms

Substances